Antidepressants for smoking cessation

Hughes, John R.; Stead, Lindsay F; Lancaster, Tim

doi:10.1002/14651858.cd000031.pub3

Cited by 417 publications

(258 citation statements)

References 228 publications

Supporting

Mentioning

235

Contrasting

Unclassified

Order By: Relevance

“…[21] Its most frequent side-effects are insomnia, dry mouth and nausea. [20] Bupropion may also reduce the seizure threshold and a seizure risk of 1/1 000 has been reported. [22] There is no evidence that selective serotonin re-uptake inhibitors (SSRIs) are effective for smoking cessation.…”

Section: Antidepressantsmentioning

confidence: 99%

“…[20] Additionally, bupropion appears to reduce long-term relapse and the weight gain associated with quitting. [21] Its most frequent side-effects are insomnia, dry mouth and nausea.…”

Section: Antidepressantsmentioning

confidence: 99%

“…[22] There is no evidence that selective serotonin re-uptake inhibitors (SSRIs) are effective for smoking cessation. [20] Nortriptyline (not registered in SA) is generally considered a secondline therapy for those who have failed NRT and bupropion/varenicline. [23] Nortriptyline is a metabolite of amitriptyline, which is available in SA.…”

Section: Antidepressantsmentioning

confidence: 99%

See 2 more Smart Citations

South African tobacco smoking cessation clinical practice guideline

et al. 2013

View full text Add to dashboard Cite

Section: Antidepressantsmentioning

confidence: 99%

“…[20] Additionally, bupropion appears to reduce long-term relapse and the weight gain associated with quitting. [21] Its most frequent side-effects are insomnia, dry mouth and nausea.…”

Section: Antidepressantsmentioning

confidence: 99%

Section: Antidepressantsmentioning

confidence: 99%

See 1 more Smart Citation

South African tobacco smoking cessation clinical practice guideline

et al. 2013

View full text Add to dashboard Cite

“…Cochrane reviews show that behavioural support provided outside of routine clinical care is effective for smoking cessation 136,137 as are NRT, 138 bupropion, 139 varenicline 140 and nortriptyline. 139 Consequently, we defined optimal, evidencebased smoking cessation support as the following two interventions combined, being provided in addition to routine clinical health care: (1) if behavioural support, defined as either the duration of time spent with a smoker (including assessment for trial entry), exceeded 30 minutes at the initial consultation and the number of further assessment and re-enforcement visits exceeded two or at least four appointments in total occurred in which brief support (5-10 minutes' duration) was given plus (2) any single pharmacotherapy treatment for which there was Cochrane review evidence for efficacy and a side effect profile which has enabled it to have widespread use in at least one country; eligible pharmacotherapies were NRT, bupropion, varenicline and nortriptyline. We excluded trials that assessed relapse prevention.…”

Section: Interventionsmentioning

confidence: 99%

“…Forty-one systematic reviews were identified, of which 12 focused on pharmacotherapies for smoking cessation. [138][139][140][144][145][146][147][148][149][150][151][152] The 12 systematic reviews were screened to identify studies that assessed specific pharmacotherapies with evidence of effectiveness. The full texts of the papers identified from the included Cochrane reviews were then screened independently by two authors (JL-B and SA or AMcN and TC) using a specially designed data extraction form to assess whether they fulfilled the pre-specified inclusion criteria (see Box 7, Figure 16).…”

Section: Process For Identifying Studiesmentioning

confidence: 99%

Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.

Coleman

Agboola²,

Leonardi‐Bee³

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA Relapse prevention in UK Stop Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch) and Current Contents / Clinical Medicine. NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in t...

show abstract

A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care

Fossati¹

2007

Arch Intern Med

View full text Add to dashboard Cite

Background: Studies undertaken in academic settings have shown that bupropion hydrochloride can double the odds of smoking cessation compared with placebo. To assess whether these results are applicable in primary care, we launched a double-blind, placebo-controlled, randomized trial to be conducted by general practitioners. Methods: We assigned 593 healthy smokers to receive bupropion hydrochloride, 150 mg twice a day, or placebo daily for 7 weeks (hereinafter, bupropion group [n=400] and placebo group [n = 193], respectively). After the baseline visit, 4 clinical visits and 3 telephone calls were scheduled over the 1-year period. The primary end points were biochemically confirmed continuous abstinence at week 7 and at week 52. Results: Seventy-one Italian general practitioners enrolled participants from April 2004 to May 2005. Of the bupropion group, 41.0% were continuously abstinent from week 4 to week 7 compared with 22.3% of the placebo group (multivariate odds ratio, 2.37; 95% confidence interval, 1.60-3.53). The continuous abstinence rates from week 4 to week 52 were 25% in the bupropion group and 14% in the placebo group (odds ratio, 2.11; 95% confidence interval, 1.32-3.39). The mean weight gain was similar in both groups and among long-term abstainers was 3 kg in women and 4 kg in men. More participants in the bupropion group experienced an adverse event than those in the placebo group, but the percentage who discontinued use of the study medication was similar. Conclusions: Bupropion more than doubled the odds of continuous abstinence from smoking. The adherence of general practitioners and participants to the protocol was excellent, making our findings robust and easy to generalize to the context of primary care.

show abstract

Antidepressants for smoking cessation

Cited by 417 publications

References 228 publications

South African tobacco smoking cessation clinical practice guideline

South African tobacco smoking cessation clinical practice guideline

Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.

A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care

Contact Info

Product

Resources

About